Xeris Biopharma Holdings Inc
NASDAQ:XERS
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.7
3.73
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Xeris Biopharma Holdings Inc
Wall Street
Price Targets
XERS Price Targets Summary
Xeris Biopharma Holdings Inc
According to Wall Street analysts, the average 1-year price target for
XERS
is 4.86 USD
with a low forecast of 3.03 USD and a high forecast of 6.93 USD.
XERS Last Price Targets
Xeris Biopharma Holdings Inc
The latest public price target was made on Nov 11, 2024 by
Oren Livnat
from
H.C. Wainwright
,
who expects
XERS
stock to
rise by 93%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
|
Oren Livnat
H.C. Wainwright
|
6.6
USD
Upside 93% |
1 month ago
Nov 11, 2024
|
Xeris Pharmaceuticals (XERS) PT Raised to $6.60 at H.C. Wainwright
StreetInsider
|
Leland Gershell
Oppenheimer
|
5
USD
Upside 46% |
2 months ago
Oct 23, 2024
|
Oppenheimer Reiterates Outperform Rating on Xeris Pharmaceuticals (XERS)
StreetInsider
|
David Amsellem
Piper Sandler
|
3
USD
Downside 12% |
7 months ago
May 10, 2024
|
Xeris Pharmaceuticals (XERS) PT Lowered to $3 at Piper Sandler
StreetInsider
|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is XERS's stock price target?
Price Target
4.86
USD
According to Wall Street analysts, the average 1-year price target for
XERS
is 4.86 USD
with a low forecast of 3.03 USD and a high forecast of 6.93 USD.
What is Xeris Biopharma Holdings Inc's Revenue forecast?
Projected CAGR
20%
For the last 6 years the
compound annual growth rate for
Xeris Biopharma Holdings Inc's revenue is
116%.
The projected
CAGR
for the next 4 years is
20%.
You don't have any saved screeners yet
